Timothy John Daskivich

Timothy John Daskivich

Auto-generated profile, based on publicly available information

Timothy John Daskivich

Department of Urology, Cedars-Sinai Medical Center, Los Angeles, USA

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2019 in JAMA Network Open
Verified
Journal Article
Open access
PDF file
TDTimothy J. Daskivich
Timothy J. Daskivich
JHJustin Houman
Justin Houman
MLMayra Lopez
Mayra Lopez
MLMichael Luu
Michael Luu
PFPhilip Fleshner
Philip Fleshner
BSBrennan Spiegel
Brennan Spiegel
Ambulatory status is a fundamental factor in management of the postoperative surgical inpatient and has been linked to both key clinical (eg, deep venous thromboembolism)1-3 and efficiency (eg, cost of inpatient care and length of stay [LOS])4-8 outcomes. Yet, despite its central role in recovery and disposition, daily assessment of ambulation is imprecise and is an often neglected component of nursing care, missed 76% to 89% of the time.9-12 Most often, assessments of daily ambulation rely on patient report, which may be inaccurate, or nursing accounts, which are difficult to ascertain due to frequent handoffs in care. Given the high stakes for poor ambulation, surgical teams have a need for better information regarding postoperative ambulation, including a simple method for quantification of an objective ambulation goal linked to a relevant clinical outcome.

8 September 2017 in Journal of the American Medical Informatics Association
Verified
Journal Article
Closed access
PDF file
TDTimothy J Daskivich
Timothy J Daskivich
JHJustin Houman
Justin Houman
GFGarth Fuller
Garth Fuller
JBJeanne T Black
Jeanne T Black
HKHyung L Kim
Hyung L Kim
BSBrennan Spiegel
Brennan Spiegel
Objective: Patients use online consumer ratings to identify high-performing physicians, but it is unclear if ratings are valid measures of clinical performance. We sought to determine whether online ratings of specialist physicians from 5 platforms predict quality of care, value of care, and peer-assessed physician performance. Materials and Methods: We conducted an observational study of 78 physicians representing 8 medical and surgical specialties. We assessed the association of consumer ratings with specialty-specific performance scores (metrics including adherence to Choosing Wisely measures, 30-day readmissions, length of stay, and adjusted cost of care), primary care physician peer-review scores, and administrator peer-review scores. Results: Across ratings platforms, multivariable models showed no significant association between mean consumer ratings and specialty-specific performance scores (β-coefficient range, −0.04, 0.04), primary care physician scores (β-coefficient range, −0.01, 0.3), and administrator scores (β-coefficient range, −0.2, 0.1). There was no association between ratings and score subdomains addressing quality or value-based care. Among physicians in the lowest quartile of specialty-specific performance scores, only 5%–32% had consumer ratings in the lowest quartile across platforms. Ratings were consistent across platforms; a physician’s score on one platform significantly predicted his/her score on another in 5 of 10 comparisons. Discussion: Online ratings of specialist physicians do not predict objective measures of quality of care or peer assessment of clinical performance. Scores are consistent across platforms, suggesting that they jointly measure a latent construct that is unrelated to performance. Conclusion: Online consumer ratings should not be used in isolation to select physicians, given their poor association with clinical performance.

22 October 2014 in Cancer
Verified
Journal Article
Open access
PDF file
KCKarim Chamie
Karim Chamie
EBEric Ballon‐Landa
Eric Ballon‐Landa
JBJeffrey C. Bassett
Jeffrey C. Bassett
TDTimothy J. Daskivich
Timothy J. Daskivich
MLMeryl Leventhal
Meryl Leventhal
MLMark S. Litwin
Mark S. Litwin
BACKGROUND: Muscle sampling is often used as a surrogate for staging quality in patients with bladder cancer. The association of staging quality at diagnosis and survival was examined among patients with bladder cancer.METHODS: The clinical records of all individuals within the Los Angeles Surveillance, Epidemiology, and End Results registry with an incident diagnosis of non–muscle‐invasive bladder cancer in 2004‐2005 were reviewed. Patient demographics, tumor characteristics, staging quality (presence of muscle in the specimen and mention of muscle in the pathology report), and vital status were recorded. With mixed‐effects and competing‐risks regression analyses, the association of patient and tumor characteristics with staging quality and cancer‐specific survival was quantified.RESULTS: The sample included 1865 patients, 335 urologists, and 27 pathologists. Muscle was reported to be present in 972 (52.1%), was reported to be absent in 564 (30.2%), and was not mentioned in 329 (17.7%) of the initial pathology reports. The presence of muscle did not differ according to the grade or depth of invasion. Mortality was associated with staging quality (P < .05). Among patients with high‐grade disease, the 5‐year cancer‐specific mortality rates were 7.6%, 12.1%, and 18.8% when muscle was present, absent, and not mentioned, respectively.CONCLUSIONS: The omission of muscle in the specimen or its mention in the pathology report in nearly half of all diagnostic resections was associated with increased mortality, particularly in patients with high‐grade disease. Because urologists cannot reliably discern between high‐ and low‐grade or Ta and T1 disease, it is contended that patients with bladder cancer should undergo adequate muscle sampling at the time of endoscopic resection. Cancer 2015;121:379–385. © 2014 American Cancer Society.

9 May 2018 in Journal of Medical Internet Research
Verified
Journal Article
Open access
TDTimothy Daskivich
Timothy Daskivich
MLMichael Luu
Michael Luu
BNBenjamin Noah
Benjamin Noah
GFGarth Fuller
Garth Fuller
JAJennifer T. Anger
Jennifer T. Anger
BSBrennan Spiegel
Brennan Spiegel
Journal of Medical Internet Research - International Scientific Journal for Medical Research, Information and Communication on the Internet

1 September 2016 in Journal of Urology
Verified
Journal Article
Closed access
TDTimothy J. Daskivich
Timothy J. Daskivich
HTHung-Jui Tan
Hung-Jui Tan
MLMark S. Litwin
Mark S. Litwin
JHJim C. Hu
Jim C. Hu
Patients with limited life expectancy are at risk for overtreatment of T1a kidney cancer. We sought to determine patterns of treatment for T1a kidney cancer in a nationally representative sample of patients with life expectancy less than 10 and less than 5 years. We sampled 9,825 patients older than 65 years with clinical T1a kidney cancer diagnosed between 2000 and 2010 from the SEER (Surveillance, Epidemiology and End Results)-Medicare database. We performed competing risks regression to model survival by age/comorbidity and identified patients with life expectancy less than 10 and less than 5 years. Multivariate logistic regression was used to determine the probability of aggressive treatment with surgery or ablation among those with limited life expectancy. Life expectancy was less than 10 years in patients 66 to 80 years old with a Charlson score of 3+, in those 80 to 84 years old with a Charlson score of 1+ and in all patients 85 years old or older. Among those with life expectancy less than 10 years the multivariate probability of aggressive treatment was 85%, 84%, 82%, 75% and 50% in those 66 to 69, 70 to 74, 75 to 79, 80 to 84 and 85 years old or older, respectively. In those with life expectancy less than 10 years who were treated aggressively treatment was radical nephrectomy in 61%, partial nephrectomy in 24% and ablation in 14%. Among those with life expectancy less than 5 years (age 85 years or greater with a Charlson score of 3+) the multivariate probability of aggressive treatment was 41% and more often surgery than ablation (68% vs 32% of patients). The majority of patients with life expectancy less than 10 years and a significant minority with life expectancy less than 5 years were treated with surgery or ablation for T1a kidney cancer. Life expectancy should be better incorporated into treatment decision making for early stage kidney cancer.

1 January 2025 in JAMA Internal Medicine
Verified
Journal Article
Closed access
TDTimothy J. Daskivich
Timothy J. Daskivich
MLMichael Luu
Michael Luu
JHJohn Heard
John Heard
ITI-Chun Thomas
I-Chun Thomas
JLJohn T. Leppert
John T. Leppert
Importance: Men with limited life expectancy (LE) have historically been overtreated for prostate cancer despite clear guideline recommendations. With increasing use of active surveillance, it is unclear if overtreatment of men with limited LE has persisted and how overtreatment varies by tumor risk and treatment type.Objective: To determine if rates of overtreatment of men with limited LE have persisted in the active surveillance era and whether overtreatment varies by tumor risk or treatment type.Design, Setting, and Participants: This cohort study included men with clinically localized prostate cancer in the Veterans Affairs health system who received a diagnosis between January 1, 2000, and December 31, 2019.Main Outcomes and Measures: LE was estimated using the validated age-adjusted Prostate Cancer Comorbidity Index (PCCI). Treatment trends among men with limited LE were assessed using a stratified linear and log-linear Poisson regression in aggregate and across PCCI and tumor risk subgroups.Results: The mean (SD) age for the study population of 243 928 men was 66.8 (8.0) years. A total of 50 045 (20.5%) and 11 366 (4.7%) men had an LE of less than 10 years and LE of less than 5 years based on PCCI scores of 5 or greater and 10 or greater, respectively. Among men with an LE of less than 10 years, the proportion of men treated with definitive treatment (surgery or radiotherapy) for low-risk disease decreased from 37.4% to 14.7% (absolute change, −22.7%; 95% CI, −30.0% to −15.4%) but increased for intermediate-risk disease from 37.6% to 59.8% (22.1%; 95% CI, 14.8%-29.4%) from 2000 to 2019, with increases observed for favorable (32.8%-57.8%) unfavorable intermediate-risk disease (46.1%-65.2%). Among men with an LE of less than 10 years who were receiving definitive therapy, the predominant treatment was radiotherapy (78%). Among men with an LE of less than 10 years, use of radiotherapy increased from 31.3% to 44.9% (13.6%; 95% CI, 8.5%-18.7%) for intermediate-risk disease from 2000 to 2019, with increases observed for favorable and unfavorable intermediate-risk disease. Among men with an LE of less than 5 years, the proportion of men treated with definitive treatment for high-risk disease increased from 17.3% to 46.5% (29.3%; 95% CI, 21.9%-36.6%) from 2000 to 2019. Among men with an LE of less than 5 years who were receiving definitive therapy, the predominant treatment was radiotherapy (85%). Among men with an LE of less than 5 years, use of radiotherapy increased from 16.3% to 39.0% (22.6%; 95% CI, 16.5%-28.8%) from 2000 to 2019.Conclusions and Relevance: The results of this cohort study suggest that, in the active surveillance era, overtreatment of men with limited LE and intermediate-risk and high-risk prostate cancer has increased in the VA, mainly with radiotherapy.